CRL - Charles River Laboratories International, Inc.
About Charles River Laboratories International, Inc. (https://www.criver.com)
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| James C. Foster | Chairman, President & Chief Executive Officer | 1951 | $3,834,131 USD |
| Birgit Girshick | CEO & Director | 1970 | $1,774,768 USD |
| Joseph W. LaPlume | Corporate Executive Vice President of Corporate Development & Strategy | 1974 | $1,252,886 USD |
| Victoria L. Creamer | Corporate Executive Vice President & Chief People Officer | 1970 | $1,225,929 USD |
| Glenn G. Coleman | Corporate Executive Vice President & Chief Financial Officer | 1968 | $930,201 USD |
| Michael Gunnar Knell | Corporate Senior Vice President & Chief Accounting Officer | 1977 | $912,225 USD |
| Amy Cianciaruso | Corporate Senior Vice President, Chief Communications Officer & Government Relations | – | – |
| Brian F. Bathgate | Corporate Senior Vice President of European Safety Assessment | 1960 | – |
| Julie Frearson | Corporate Senior Vice President & Chief Scientific Officer | – | – |
| Kerry Dailey | Corporate Senior VP & Chief Legal Officer | – | – |
| Mark Mintz | Corporate EVP, Chief Information Officer & Global Shared Services | 1974 | – |
| Matthew L. Daniel | Corporate Senior Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer | – | – |
| Todd Spencer | Corporate Vice President of Investor Relations | – | – |